Aim: Lenvatinib (LEN) has recently become available as a firstline tyrosine-kinase inhibitor (TKI) for unresectable hepatocellular carcinoma (u-HCC). In patients who showed intolerability or failure in other TKI treatments, alternative treatment options are needed. This retrospective study evaluated the therapeutic potential of LEN in clinical practice.
INTRODUCTION

L
IVER CANCER, WHICH is nearly always hepatocellular carcinoma (HCC), has been reported to be the sixth most common type of cancer and third most common cause of cancer death worldwide. 1 Tyrosine-kinase inhibitors (TKIs), such as sorafenib (SOR) 2, 3 and regorafenib (REG), 4, 5 are used for patients with unresectable HCC (u-HCC) in many countries. Regorafenib is a second-line TKI given to patients with SOR failure, although not all patients initially treated with SOR can be treated with REG after progression is noted, [6] [7] [8] [9] because the criteria for switching to REG therapy at the time of first radiological confirmation of progressive disease (PD) are strictly defined, with reference to the eligibility criteria in the RESORCE trial. 4 Recently, lenvatinib (LEN), a new TKI, 10, 11 has become available as a first-line drug for u-HCC in Japan. Patients with u-HCC who show intolerability for SOR or failure of another TKI need second-and third-line treatment options. This study aimed to evaluate early therapeutic response to LEN given for u-HCC in clinical practice, including patients who had previously received another TKI.
METHODS
F
ROM MARCH TO June 2018, LEN was given to 57 u-HCC patients at 12 different institutions in Japan: Ehime Prefectural Central Hospital (n = 16), Okayama City Hospital (n = 8), Kagawa Prefectural Central Hospital (n = 8), Ogaki Municipal Hospital (n = 6), Otakanomori Hospital (n = 4), Asahi General Hospital (n = 3), Toyama University Hospital (n = 3), Tokushima Prefectural Central Hospital (n = 3), Teine Keijinkai Hospital (n = 2), Saiseikai Niigata Daini Hospital (n = 2), Ehime University Hospital (n = 1), and Matsuyama Red Cross Hospital (n = 1). Those patients were enrolled and clinical data obtained at introduction of LEN, and 2 and 4 weeks later were examined in a retrospective manner. After exclusion of patients whose initial LEN dose was reduced, clinical characteristics and early therapeutic response were analyzed (Fig. 1) .
Patients positive for anti-hepatitis C virus (HCV) were judged to have HCC due to HCV and those positive for hepatitis B virus surface antigen were judged to have HCC due to hepatitis B virus (HBV).
Methods for assessment of hepatic reserve function and prognosis
Child-Pugh classification 12 and albumin-bilirubin (ALBI) grade were used to assess hepatic reserve function. The ALBI grade was calculated based on serum albumin and total bilirubin values using the following formula:
, and defined by the following scores: ≤ À2.60 = grade 1; > À2.60 to ≤ À1.39 = grade 2; and > À1.39 = grade 3.
13-15
Diagnosis and treatment of HCC Hepatocellular carcinoma was diagnosed based on an increasing course of α-fetoprotein, as well as dynamic computed tomography (CT), 16 magnetic resonance imaging (MRI), 17, 18 contrast-enhanced ultrasonography with perflubutane (Sonazoid; Daiichi Sankyo, Tokyo, Japan), 19, 20 and/or pathological findings. Tumor-nodemetastasis (TNM) stage was determined as previously reported in studies for staging of HCC undertaken by the Liver Cancer Study Group of Japan. 21 The present study 
Lenvatinib treatment and adverse events assessment
Lenvatinib (Eisai, Tokyo, Japan) was given orally to patients weighing <60 kg at 8 mg/day and at 12 mg/day to those ≥60 kg after obtaining written informed consent, and discontinued when any unacceptable or serious adverse events (AEs) or clinical tumor progression were observed. According to the guideline for administration of LEN, the drug dose should be reduced or the treatment interrupted when a patient develops ≥grade 3 severe AEs or any unacceptable grade 2 drug-related AEs occur. Adverse events were assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0. 22 If a drug-related AE occurred, dose reduction or temporary interruption was maintained until the symptom was resolved to grade 1 or 2, according to the guidelines provided by the manufacturer.
Evaluation of therapeutic response
Local physicians at each institution evaluated tumors using enhanced CT or MRI at 4 weeks after introducing LEN, in accordance with the modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
23,24
Statistical analysis
Data are expressed as the mean and standard deviation. Statistical analyses were carried out using Welch's t-test, the Fischer's exact test, and the Mann-Whitney U-test. A P-value less than 0.05 was considered to indicate statistical significance. For multiple comparisons, Holm's method was used. All statistical analyses were undertaken using Easy R (EZR) version 1.29 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), 25 a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
F
OLLOWING EXCLUSION OF patients whose initial LEN dose was reduced, a total of 49 patients were analyzed; their characteristics are shown in Table 1 . The average observation period after introducing LEN was 31.0 ± 22.3 days. There were 29 (59.2%) with a past history of SOR treatment, including six also treated with REG (20.7%). Although there were significant differences only in age and the frequency of history of hypertension between the patients with and without history of previous TKI treatment, hepatic reserve function and tumor burden showed no significant differences (Table 1) .
Twenty-seven patients were evaluated using imaging findings obtained by enhanced CT/MRI at 4 weeks after introducing LEN. Partial response was noted in 11, stable disease in 12, and PD in 4 (overall response rate [ORR], 40.7%; disease control rate [DCR], 85.2%). In nine patients with TNM stage II and III, ORR was 22.2% (2/9) and DCR was 77.8% (7/9); ORR was 50% (9/18) and DCR was 88.9% in those with stage IV (16/18). Of those 27 patients, eight were TKI-naïve. For the eight TKI-naïve patients, CT/MRI findings at 4 weeks after starting LEN showed an ORR of 50.0% (4/8) and DCR of 87.5% (7/8). Nineteen of those 27 were TKI-experienced patients. Lenvatinib was given as second-line treatment after SOR in 15 patients and as third-line treatment after REG in four. For the 19 patients previously treated with another TKI, CT/MRI findings at 4 weeks after starting LEN showed an ORR of 36.8% (7/19) and DCR of 84.2% (16/19) . There were no significant differences in ORR or DCR between the two groups (P = 0.675 and P = 1.00, respectively).
We examined the clinical course of 17 patients at 2 weeks and 32 patients at 4 weeks after beginning LEN therapy. There were five patients without follow-up imaging at 4 weeks. Adverse events following the start of LEN in these patients are shown in Table 2 . There was no G4 AE during the observation period. Hand-foot syndrome (HFS) was most common in the present cohort (all grades, n = 17; G3, n = 4), followed by general fatigue, appetite loss, and diarrhea. Lenvatinib treatment was paused in 10 patients and restarted with reduced dose due to AEs. Lenvatinib was abandoned in six patients due to PD (n = 2) and AEs (n = 4), of whom two were switched to hepatic arterial infusion chemotherapy. One patient with stage IVb HCC at the start of LEN stopped treatment because of severe AE (hepatic coma) on day 9, and died due to hepatic failure on day 20. At the start of LEN, the patient's Child-Pugh score was 6, but the ALBI score was worse (À1.89).
Case report
A representative case is presented. A 69-year-old Japanese woman (height, 153.4 cm; body weight, 48.3 kg) was referred to our hospital for HCC (single, 2.5 cm in diameter). She had a history of HBV infection, as well as surgical resection of breast cancer and gastric cancer. Radiofrequency ablation was undertaken as the initial therapy and regular follow-up imaging examinations were carried out, with recurrence beyond the Milan criteria 26 pointed out after 9 months. Following two transcatheter arterial chemoembolization (TACE) procedures, TACE refractory status was confirmed and SOR was introduced (initial dose
, body weight loss (5 kg) (grade 2), and PD in follow-up CT findings. Although peritoneal dissemination was suspected in CT images, REG was not indicated because of the AEs, which had lowered quality of life. Retreatment with TACE was attempted before LEN became available, but rapid progression of intrahepatic lesions occurred. Finally, LEN was started in April 2018 with informed consent, which resulted in no significant AEs and a good therapeutic response obtained after 4 weeks (Fig. 2) .
DISCUSSION
F OLLOWING THE INTRODUCTION of SOR, it was difficult to develop a new TKI for treatment of u-HCC. Four global trials were completed (sunitinib, 27 brivanib, 28 linifanib, 29 and erlotinib plus SOR 30 ) but none showed superiority and all ended in failure. Finally, REG 4,5 was produced as a second-line option of SOR in patients who met the RESORCE trial criteria and, more recently, LEN 11 was developed as a first-line drug. The therapeutic efficacy of REG for prolonging prognosis as second-line treatment 26.3 ± 17.5 34.6 ± 25.0 P = 0.186 †Overlapping cases. AFP, α-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; EHM, extrahepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; LCSGJ 6th, Liver Cancer Study Group of Japan, 6th edition; LN, lymph node; MVI, major venous invasion; PS, performance status; REG, regorafenib; SOR, sorafenib; TKI, tyrosine kinase inhibitor; TNM, tumor-node-metastasis. *[Correction added on 13 December 2018, after first online publication: The data in the last 3 columns of the naïve : recurrence row in Table 1 have been corrected from 3:17 to 4:16, 1:28 to 0:29, P = 0.291 to P = 0.014 respectively]. 
BW, body weight; HFS, hand-foot syndrome; TKI, tyrosine kinase inhibitor.
-, no setting for the applicable grade in the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0. *[Correction added on 13 December 2018, after first online publication: In Table 2 , the headings 'SOR naïve (n = 20)' has been amended to 'TKI naïve (n = 20)' and 'SOR experienced (n = 29)' has been amended to 'TKI experienced (n = 29)'. TKI refers to tyrosine kinase inhibitor. The Grade 2 data for hypothyroidism has also been corrected from 0 to 1. in u-HCC patients with good hepatic function, and who showed tolerability for SOR, has been reported. 4 Thereafter, LEN became available as a first-line oral TKI targeting vascular endothelial growth factor receptors 1-4, plateletderived growth factor receptor α, RET, and KIT. 11 In clinical practice, all patients treated with SOR do not meet the RESORCE trial criteria. Thus, the frequency of u-HCC patients indicated for REG has been reported to range from only 30.6% to 37.0% of those confirmed by radiological findings to have PD with SOR therapy. [6] [7] [8] [9] Absence of a therapeutic option for second-line treatment other than REG in u-HCC patients who do not meet the eligibility criteria for the RESORCE trial (tolerability for SOR) is an important clinical issue. Furthermore, there is no information available regarding whether LEN is a therapeutic option as second or third-line treatment for u-HCC after failure of SOR. Although the number of patients analyzed in the present study was small, our findings showed good therapeutic response with LEN treatment not only in TKI-naïve u-HCC patients, but also in those who experienced TKI. In the present study, there was no significant difference in ORR or DCR at 4 weeks after introducing LEN between patients with and without history of TKI treatments.
It is well known that the prognosis of HCC is influenced by tumor progression as well as hepatic reserve function.
14,31 Presently, three TKIs are available for treatment of patients with u-HCC. We found that TKI-experienced patients had similar hepatic reserve function (Child-Pugh score and ALBI grade/score) to those of TKI-naïve patients. In the present analysis, one patient died due to hepatic dysfunction. Ogasawara et al. divided ALBI grade 2 by ALBI score À2.118 into 2A and 2B in patients treated with SOR. They reported that the prognosis of those with 2B (>À2.118) was worse than with 2A (median survival time 6.6 vs. 14.4 months; P = 0.004). 32 Recently, the modified ALBI grade has been reported, which has two subgrades (2a and 2b) divided by ALBI score À2.270 as the cut-off value of the indocyanine green retention rate at 15 min at 30%. 33, 34 Such detailed assessment of hepatic reserve function might be useful not only in curative treatments but also in TKI treatments. When ALBI score shows a lower level of subgrade of grade 2 even in patients with ChildPugh A, we should keep in mind the risk of hepatic dysfunction by LEN. In order to maintain a variety of therapeutic options for u-HCC, it is important to maintain hepatic reserve function during the TACE course and adequately judge TACE refractory status when receiving treatment for Barcelona Clinic Liver Cancer B(BCLC-B) stage HCC. 35 A previous study of u-HCC patients undergoing SOR treatment showed that the prognosis of patients with ALBI grade 2 was worse compared to those with ALBI grade 1, even those with good hepatic function, such as Child-Pugh score 5. 36 In the present multiple TKI era, it has become more important to carefully consider the indications for retreatment with TACE or switching to a TKI.
The present study has some limitations, including its retrospective nature. Additionally, although this was a multicenter study, the number of analyzed patients was small. Furthermore, the results showed only early therapeutic response to LEN and its therapeutic potential. Patient prognosis should be compared with other TKIs using findings obtained in a randomized control trial.
In summary, our results showed that LEN might have therapeutic potential for u-HCC patients as not only firstline but also second-line treatment.
